Pure Cardarine

Description

Pure Cardarine, also known as GW-501516 or Endurobol, is a synthetic compound. Scientists originally developed it as a potential treatment for metabolic and cardiovascular diseases. However, contrary to popular belief, Cardarine is not a SARM. Instead, it functions as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. Ligand Pharmaceuticals and GlaxoSmithKline (GSK) initially developed this compound in the 1990s. They targeted obesity, diabetes, and lipid disorders. The compound has a molecular formula of C21H18F3NO3S2. It has a molecular weight of 453.5 g/mol. For further reading on related compounds, explore our guide on SARMs and research chemicals. Additionally, external regulatory information is available from the World Anti-Doping Agency and the U.S. Food and Drug Administration.

How Does Cardarine Work at the Molecular Level?

Moving on to its mechanism, Cardarine functions as a high-affinity agonist of the PPARδ receptor. When Cardarine binds to these nuclear receptors, it triggers a cascade of transcriptional changes. These changes fundamentally alter cellular metabolism. Specifically, it activates genes involved in fatty acid oxidation. It also promotes mitochondrial biogenesis and energy expenditure. This activation upregulates key proteins like CPT1 (carnitine palmitoyltransferase I). It also upregulates PDK4 (pyruvate dehydrogenase kinase 4). These shifts move the body’s energy utilization from glucose to fat. Consequently, the compound effectively mimics the physiological effects of exercise. This has earned it the nickname “exercise in a pill.” Furthermore, Cardarine stimulates the production of Type I (slow-twitch) muscle fibres. These fibres are more efficient at burning fat for energy during prolonged activity.

What Are the Potential Benefits and Uses?

Turning our attention to clinical applications, Cardarine has demonstrated several potential benefits in research settings. Specifically, studies have shown it can increase fat oxidation. It also enhances endurance capacity, improves insulin sensitivity, and regulates blood lipid profiles. For example, preclinical studies demonstrated decreases in triglycerides of approximately 30-50%. They also showed increases in HDL cholesterol of about 20-30%. Additionally, the compound appears to improve glucose tolerance. It also reduces intramuscular lipid accumulation. However, researchers have never completed human clinical trials for these indications. No good scientific evidence supports these uses. For more information on supplementation safety, refer to our supplement safety guidelines.

What Are the Critical Side Effects and Risks?

Despite its appeal, we must acknowledge the significant safety concerns associated with Cardarine. Firstly, GSK terminated development of this compound in 2007. Preclinical toxicology reports linked it to rapid carcinogenesis in multiple organs. A 104-week bioassay in Han Wistar rats and CD-1 mice showed the development of neoplasms. These included hepatocellular carcinoma in the liver. They also included gastric tumors and urothelial carcinoma in the bladder. Researchers observed this cancer risk at large doses. It was consistent and dose-dependent. Secondly, the FDA has issued warning letters to companies selling Cardarine. The agency emphasizes that it is not safe for human consumption. It cannot be legally marketed as a dietary supplement. Thirdly, regulatory bodies have classified it under Schedule 10. This means it poses such a danger to health that it is prohibited by law from sale, supply, and use. Other commonly reported side effects include liver toxicity, cardiovascular complications, and hormonal disruption. Additionally, a recent study found that Cardarine facilitates tumor immune escape by inhibiting phagocytosis.

Why Is Regulatory Status a Major Concern?

Another critical issue involves the compound’s legal and regulatory status. Cardarine is not approved by the FDA for human consumption. It is not listed on the Australian Register of Therapeutic Goods. The FDA explicitly excludes Cardarine from the definition of dietary supplements. Supplements containing Cardarine are illegal. Furthermore, WADA added Cardarine to its Prohibited List in 2009. It falls under category S4 ‘Hormone and Metabolic Modulators’. In 2023, there were 54 occurrences of Adverse Analytical Findings related to GW1516. This accounts for 17% of all AAFs within section S4.4. Consequently, athletes who use it risk significant sanctions. Moreover, sellers often market it as a research chemical. This means purity and dosage of online products frequently remain unverified. WADA issued a rare “Health Warning” in 2013. They aimed to dissuade athletes from using black-market sources. As a result, this lack of quality control and regulatory oversight adds additional risk for consumers.

Final Verdict and Recommendations

In conclusion, Pure Cardarine represents a fascinating research area for PPARδ agonism. It shows potential applications in metabolic disorders and endurance enhancement. However, for the general public or athletes, using Cardarine carries significant health risks. These include potentially fatal cancer risk, liver toxicity, cardiovascular strain, and unknown long-term effects. Furthermore, the lack of regulatory approval and high potential for contaminated products exacerbate these dangers. Sport Integrity Australia warns that, “Athletes seeking to obtain an ‘edge’ from the use of GW1516 need to be aware that they risk more than a positive test if they choose to take it – they may be risking their life.” Therefore, we strongly advise anyone considering its use to thoroughly research the clinical literature. Users must understand the severe implications of misuse. Ultimately, consulting a medical professional before using any unregulated research compound is not just recommended—it is essential.